Vol. 1 No. 11 (2021)
Reimbursement Reviews

Risdiplam (Evrysdi)

Published November 1, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses risdiplam (Evrysdi), powder for oral solution.
  • Indication:
    • Pre-NOC: for the treatment of spinal muscular atrophy;
    • Final: for the treatment of spinal muscular atrophy in patients 2 months and older.